MYCN and neuroblastoma: Here we identify, for the first time, the efficacy of miR-34a in retarding neuroblastoma tumor growth in vivo in both MYCN amplified (NB1691luc) and non-MYCN amplified (SK-N-ASluc) neuroblastoma xenografts; and also propose a potential mechanism through which this might occur.